For Research Use Only. Semax is intended strictly for in vitro and preclinical animal research. It is not approved for human use, is not a drug, and should never be administered to humans.
Retinal Neurobiology and Neurotrophins
The retina is a highly specialized neural tissue with photoreceptors, bipolar cells, ganglion cells, and supporting glial cells. The retinal ganglion cells extend axons that form the optic nerve, which is a central nervous system tract rather than a peripheral nerve despite its name. The retinal and optic nerve biology is therefore closely related to brain neurobiology, and neuroprotective mechanisms that operate in brain tissue generally apply to retinal tissue as well.
Brain derived neurotrophic factor and nerve growth factor both support retinal ganglion cell survival and function. The Semax BDNF NGF article in this cluster covers the broader neurotrophin biology. In the retinal context, the neurotrophin support is particularly important because retinal ganglion cells are the sole output neurons of the retina, and their loss produces irreversible visual deficits.
The Nature subject hub on retinal biology and the ScienceDirect retinal ganglion cell topic page archive primary research on the retinal neurobiology.
Optic Nerve Crush Model Research
The optic nerve crush model is a standard research platform for examining neuroprotective interventions in the visual system. The model produces defined optic nerve axonal injury that triggers retrograde ganglion cell degeneration over days to weeks. Neuroprotective interventions can be tested by measuring retinal ganglion cell survival at defined time points after the injury.
Published Semax research in optic nerve crush models documents preserved retinal ganglion cell density, maintained axonal integrity, and preserved visual evoked responses in treated animals compared to vehicle controls. The protective effects align with the BDNF and NGF mediated neuroprotection documented in other Semax research contexts, applied to the retinal neurons that depend particularly strongly on neurotrophin signaling for survival.
The optic nerve crush research connects to the Semax ischemia article through the shared neurotrophin biology, although the specific injury mechanisms differ between ischemic brain injury and mechanical optic nerve injury.
The Cell Press journal Neuron archives primary research on optic nerve biology.
Glaucoma Research Models
Glaucoma models using elevated intraocular pressure produce retinal ganglion cell loss that recapitulates aspects of the human disease. Published Semax research in glaucoma models documents preserved retinal ganglion cell density and preserved visual function endpoints in treated animals compared to controls.
The glaucoma research extends the acute optic nerve injury research into the chronic progressive injury context. The findings support the interpretation that Semax neuroprotection operates not only in acute injury settings but also in chronic progressive neurodegenerative contexts within the visual system.
The glaucoma research connects to the broader neurodegeneration research across the Midwest Peptide catalog. The NAD+ neurodegeneration article covers general brain neurodegeneration, and some of the pathological mechanisms involved in glaucoma overlap with the mechanisms of central neurodegenerative pathology.
The Wiley Online Library ophthalmology collection archives primary research on glaucoma models.
Ischemic Retinopathy Research
Retinal ischemia models produce defined retinal injury that has been used to examine Semax protective effects. Central retinal artery occlusion models, oxygen induced retinopathy models, and diabetic retinopathy models all produce ischemic retinal injury through different mechanisms. Published Semax research in these models documents protective effects across the various ischemic injury types.
The retinal ischemia research connects to the Semax ischemia article which covers cerebral ischemia, through the shared injury mechanism. The retinal tissue and the brain tissue both depend on adequate vascular supply and both suffer characteristic damage patterns under ischemic conditions. The same neurotrophin mediated protective mechanisms that benefit brain tissue also benefit retinal tissue.
The Frontiers in Neuroscience open access journal archives primary research on retinal ischemia.
Intranasal Delivery to Retinal Tissue
The intranasal delivery article in this cluster covers the intranasal administration route that is commonly used for Semax research. The intranasal route provides direct access to the central nervous system through the olfactory and trigeminal nerve pathways. For retinal applications specifically, the intranasal route provides relatively direct access to the retinal and optic nerve tissue through the continuous central nervous system compartment.
The delivery route considerations are particularly relevant for ophthalmologic research because the blood retinal barrier limits direct systemic delivery to retinal tissue. Intranasal administration partially bypasses this barrier by providing alternative access through the central nervous system compartment. Other delivery routes including intravitreal injection provide direct retinal delivery but require surgical administration.
Retinal Gene Expression Under Semax
Published research on retinal gene expression under Semax administration documents upregulation of BDNF and NGF in retinal tissue, consistent with the broader neurotrophin biology of the peptide. The upregulated neurotrophin expression in retinal tissue provides the local mechanism for the retinal ganglion cell protection documented at the cellular level.
The gene expression data complements the cellular and functional endpoints by providing the mechanistic link between peptide administration and retinal protection. The same transcriptional mechanisms that operate in brain tissue under Semax administration operate in retinal tissue, which is consistent with the shared central nervous system biology of the two tissue types.